Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical...
73 insider purchases on record · latest filing 2025-05-22.
Insiders have also filed 641 sale transactions at INSM.